BEGIN:VCALENDAR VERSION:2.0 PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.27.21// CALSCALE:GREGORIAN BEGIN:VEVENT UID:918b4c3ba6995f9a7e7d6fac8ae3db67107d606d@swoogo.com DTSTAMP:20240328T114132Z DESCRIPTION:Technology advancements\, broad-based commercialization of wear ables and sensors\, and the impact of a global pandemic are proving to be pivotal in the shift towards decentralized clinical trials. The ability fo r remote\, unobtrusive and real-time capture of patient data coupled with the need to reduce in-person contact is accelerating the life sciences ind ustry’s interest in new approaches to clinical trials. This use of sensors and real-time data capture vastly improves the quality of clinical data w ith the potential to reduce site queries and monitoring visits. There is a lso unprecedented accessibility to vast volumes of patient data – and the ability to apply artificial intelligence and machine learning in the analy sis of that data – all powering new safety and clinical insights. In this session\, Cognizant will explore current state of technology\, the impact of regulatory oversight\, and readiness of the industry to drive necessary changes.\n DTSTART:20210622T165000Z DTEND:20210622T172000Z LAST-MODIFIED:20240328T114132Z LOCATION:https://healthsciences21.isg-one.com/home/v/s-509097 SEQUENCE:0 STATUS:CONFIRMED SUMMARY:FEATURED PRESENTATION: Accelerating the Adoption of Decentralized C linical Trials TRANSP:OPAQUE X-ALT-DESC;FMTTYPE=text/html:
Technology advancements\, broad-based comme rcialization of wearables and sensors\, and the impact of a global pandemi c are proving to be pivotal in the shift towards decentralized clinical tr ials. The ability for remote\, unobtrusive and real-time capture of patien t data coupled with the need to reduce in-person contact is accelerating t he life sciences industry’s interest in new approaches to clinical trials. This use of sensors and real-time data capture vastly improves the qualit y of clinical data with the potential to reduce site queries and monitorin g visits. There is also unprecedented accessibility to vast volumes of pat ient data – and the ability to apply artificial intelligence and machine l earning in the analysis of that data – all powering new safety and clinica l insights. In this session\, Cognizant will explore current state of tech nology\, the impact of regulatory oversight\, and readiness of the industr y to drive necessary changes.
BEGIN:VALARM ACTION:DISPLAY DESCRIPTION:Technology advancements\, broad-based commercialization of wear ables and sensors\, and the impact of a global pandemic are proving to be pivotal in the shift towards decentralized clinical trials. The ability fo r remote\, unobtrusive and real-time capture of patient data coupled with the need to reduce in-person contact is accelerating the life sciences ind ustry’s interest in new approaches to clinical trials. This use of sensors and real-time data capture vastly improves the quality of clinical data w ith the potential to reduce site queries and monitoring visits. There is a lso unprecedented accessibility to vast volumes of patient data – and the ability to apply artificial intelligence and machine learning in the analy sis of that data – all powering new safety and clinical insights. In this session\, Cognizant will explore current state of technology\, the impact of regulatory oversight\, and readiness of the industry to drive necessary changes.\n TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR